PLUS1
6.10
0.18 (3.04%)
0.18 (3.04%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vaxart Inc | VXRT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.18 | 3.04% | 6.10 | 19:59:08 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.1252 | 5.28 | 6.17 | 6.02 | 5.92 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 6.00 | 6.09 | 0.09 | 1 | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 44,972 | 9,166,736 | $ 5.76 | $ 52,774,391 | 7,752,560 | 1.08 - 24.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:22 | 9 | $ 6.09 | USD |
Vaxart Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 667.76M | 109.47M | 83.54M | $ 9.86M | $ - | -0.79 | -59.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Vaxart News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/05/2021 | 16:04 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 3/03/2021 | 09:49 | Seeking Alpha | Vaxart CEO defends oral COVID-19 vaccine, but shares fall 8%.. |
| 2/25/2021 | 17:42 | Seeking Alpha | Vaxart EPS misses by $0.07, misses on revenue |
| 2/25/2021 | 16:22 | Edgar (US Regulatory) | Annual Report (10-k) |
| 2/25/2021 | 16:05 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/04/2021 | 15:26 | TipRanks | Vaxart Stock Takes a Hit, but Is It Warranted? Analyst.. |
| 2/04/2021 | 03:12 | TipRanks | Vaxart Tanks 58% On Oral COVID-19 Vaccine Early Trial Data;.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VXRT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.33 | 7.82 | 5.28 | 6.66 | 7,349,091 | -1.23 | -16.78% |
| 1 Month | 8.66 | 9.94 | 5.28 | 7.91 | 12,761,634 | -2.56 | -29.56% |
| 3 Months | 7.34 | 24.90 | 5.28 | 10.10 | 15,875,613 | -1.24 | -16.89% |
| 6 Months | 5.545 | 24.90 | 3.50 | 8.25 | 16,773,143 | 0.555 | 10.01% |
| 1 Year | 2.18 | 24.90 | 1.08 | 8.14 | 17,016,345 | 3.92 | 179.82% |
| 3 Years | 5.26 | 24.90 | 0.2543 | 7.24 | 6,657,741 | 0.84 | 15.97% |
| 5 Years | 17.27 | 24.90 | 0.2543 | 7.26 | 4,144,994 | -11.17 | -64.68% |
Vaxart Description
| Vaxart Inc is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus. |
